2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161230
    HSD17B13-IN-75 2770246-20-1 98%
    HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-75
  • HY-161231
    HSD17B13-IN-78 2770246-21-2 98%
    HSD17B13-IN-78 (22) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-78
  • HY-161232
    HSD17B13-IN-79 2770246-31-4 98%
    HSD17B13-IN-79 (Compound 32) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-79 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-79
  • HY-161265
    HIF-2α agonist 3 98%
    HIF-2α agonist 3 (Compound 14d) is an orally active HIF-2α agonist with a EC50 value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia.
    HIF-2α agonist 3
  • HY-161281
    α-Glucosidase-IN-49 98%
    α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice.
    α-Glucosidase-IN-49
  • HY-161316
    NNMT-IN-5 98%
    NNMT-IN-5 (Compound 3-12) is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 47.9 ± 0.6 nM). NNMT-IN-5 also has an excellent selectivity profile over a panel of human methyltransferases. NNMT-IN-5 can be used for the research of cancer, diabetes, metabolic disorders, and neurodegenerative diseases.
    NNMT-IN-5
  • HY-161318
    α-Glucosidase-IN-52 98%
    α-Glucosidase-IN-52 (Compound 3h) is an α-glucosidase inhibitor with an IC50 of 2.8 μM. α-Glucosidase-IN-52 can be used for diabetes research.
    α-Glucosidase-IN-52
  • HY-161355
    α-Amylase/α-Glucosidase-IN-9 98%
    α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes.
    α-Amylase/α-Glucosidase-IN-9
  • HY-161363
    ERK2 allosteric-IN-1 872591-16-7 98%
    ERK2 allosteric-IN-1 (compound 1) is a selective and allosteric ERK2 inhibitor with the IC50 of 11 μM.
    ERK2 allosteric-IN-1
  • HY-161411
    α-Glucosidase-IN-60 98%
    α-Glucosidase-IN-60 (Compound 5k) exhibits a competitive inhibitory efficacy against α-Glucosidase, with IC50 of 10.8 μM.
    α-Glucosidase-IN-60
  • HY-161421
    α-Glucosidase-IN-61 98%
    α-Glucosidase-IN-61 (Compd 1j), a competitive α-glucosidase inhibitor, demonstrates excellent inhibition with an IC50 of 0.73 μM. α-Glucosidase-IN-61 (Compd 1j) is used for the research of type 2 diabetes mellitus.
    α-Glucosidase-IN-61
  • HY-161428
    ZINC000003015356 872861-28-4 98%
    ZINC000003015356 is a DPP4 inhibitor.
    ZINC000003015356
  • HY-161429
    Antidiabetic agent 5 2152667-21-3 98%
    Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes.
    Antidiabetic agent 5
  • HY-161434
    PCSK9-IN-26 3033361-09-7 98%
    PCSK9-IN-26 (Compound 116) is an PCSK9 inhibitor (IC50 < 1 nM). PCSK9-IN-26 can be used for metabolic research.
    PCSK9-IN-26
  • HY-161435
    PCSK9-IN-27 98%
    PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake.
    PCSK9-IN-27
  • HY-161469
    α-Amylase/α-Glucosidase-IN-13 98%
    α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of α-Amylase/α-Glucosidase that can be used for diabetes research.
    α-Amylase/α-Glucosidase-IN-13
  • HY-161507
    hCAI/II-IN-8 3036136-18-9 98%
    hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). ..
    hCAI/II-IN-8
  • HY-161523
    XOR/URAT1-IN-1 2810137-86-9 98%
    XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model.
    XOR/URAT1-IN-1
  • HY-161660
    DS44470011 1192586-35-8 98%
    DS44470011 is a hypoxia-inducing factor prolyl hydroxylase (HIF-PHD) inhibitor. DS44470011 has oral activity. DS44470011 promotes cell release of erythropoietin (EPO). DS44470011 can be used in the research of renal anemia.
    DS44470011
  • HY-161764
    α-Glucosidase-IN-67 98%
    α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC50 values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes.
    α-Glucosidase-IN-67
Cat. No. Product Name / Synonyms Application Reactivity